Skip to main content

Table 3 Age-adjusted geometric mean of relative leukocyte telomere length (LTL) in relation to participant characteristics

From: Leukocyte telomere length and its association with mammographic density and proliferative diagnosis among women undergoing diagnostic image-guided breast biopsy

 

All women (N = 195)

Proliferative diagnosis1 (N = 141)

Non-proliferative diagnosis2 (N = 54)

P-heterogeneity¥

Characteristics

Mean LTL§

(95 % CI) §

Mean LTL§

(95 % CI) §

Mean LTL§

(95 % CI) §

 

Age (years)

      

0.817

  < 45

1.27

(1.05, 1.55)

1.47

(1.13, 1.91)

1.07

(0.80, 1.42)

 

 45–49

1.35

(1.14, 1.60)

1.47

(1.20, 1.80)

1.10

(0.81, 1.50)

 

 50–54

1.39

(1.17, 1.64)

1.46

(1.21, 1.77)

1.16

(0.82, 1.64)

 

  ≥ 55

1.23

(1.04, 1.45)

1.31

(1.09, 1.58)

0.94

(0.65, 1.37)

 

 P-trend

0.774

0.423

0.745

 

Body mass index (Kg/m2)

      

0.194

  < 25.0

1.24

(1.10, 1.39)

1.35

(1.18, 1.55)

0.93

(0.73, 1.17)

 

 25.0–29.9

1.29

(1.09, 1.52)

1.44

(1.17, 1.78)

1.09

(0.83, 1.42)

 

  ≥ 30

1.56

(1.29, 1.90)

1.57

(1.26, 1.96)

1.56

(1.05, 2.31)

 

 P-trend

0.058

0.248

0.030

 

Age at menarche (years)

      

0.743

  ≤ 12

1.26

(1.09, 1.45)

1.33

(1.13, 1.57)

1.01

(0.74, 1.37)

 

 13

1.36

(1.17, 1.58)

1.53

(1.28, 1.83)

1.08

(0.83, 1.41)

 

  ≥ 14

1.33

(1.11, 1.58)

1.43

(1.17, 1.75)

1.08

(0.76, 1.53)

 

 P-trend

0.613

0.530

0.787

 

Parity

      

0.739

 Parous

1.30

(1.17, 1.43)

1.39

(1.24, 1.55)

1.07

(0.88, 1.30)

 

 Nulliparous

1.35

(1.14, 1.61)

1.53

(1.23, 1.89)

1.08

(0.81, 1.44)

 

Age at first birth (years)*

      

0.744

  < 30

1.21

(1.08, 1.37)

1.30

(1.13, 1.50)

1.00

(0.79, 1.26)

 

  ≥ 30

1.51

(1.24, 1.83)

1.66

(1.31, 2.10)

1.28

(0.90, 1.81)

 

 P-trend

0.066

0.084

0.246

 

Menopausal status

      

0.361

 Premenopausal

1.37

(1.19, 1.57)

1.40

(1.18, 1.66)

1.22

(0.98, 1.51)

 

 Postmenopausal

1.21

(0.98, 1.50)

1.45

(1.15, 1.82)

0.74

(0.47, 1.17)

 

Age at menopause (years)

      

0.221

  < 45

1.37

(1.03, 1.84)

1.79

(1.30, 2.46)

0.67

(0.39, 1.17)

 

 45–49

1.19

(0.94, 1.52)

1.28

(0.99, 1.66)

1.18

(0.68, 2.05)

 

  ≥ 50

1.24

(1.04, 1.48)

1.31

(1.09, 1.58)

0.80

(0.52, 1.22)

 

 P-trend

0.655

0.166

0.654

 

Menopausal hormone therapy use‡

      

0.461

 Never

1.13

(0.95, 1.35)

1.26

(1.02, 1.57)

0.89

(0.60, 1.34)

 

 Ever

1.49

(1.22, 1.80)

1.50

(1.23, 1.84)

1.10

(0.60, 2.01)

 

First degree family history of breast cancer

      

0.883

 No

1.25

(1.13, 1.38)

1.35

(1.20, 1.51)

1.03

(0.85, 1.25)

 

 Yes

1.50

(1.27, 1.78)

1.64

(1.34, 2.00)

1.19

(0.87, 1.61)

 
  1. 1Diagnosis of hyperplasia, in-situ cancer or invasive cancer
  2. 2Diagnosis of benign or other discrete non-proliferative diagnosis
  3. §Based on linear regression with the log-transformed of the relative telomere length as outcome. Results are back-transformed. All characteristics were adjusted for age (continuous) and BMI (continuous), except age and BMI respectively
  4. ¥P-value based on a Wald test in the regression model corresponding to an interaction term of the proliferative disease variable times the corresponding variable (coded in continuous form)
  5. *Restricted to parous women
  6. ‡Restricted to post-menopausal women
  7. The bolded numbers indicate statistical significance results at the 5 % level
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us